David W. Gryska
CIK: 0001202335
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Oct 1, 2026CELC
Celcuity Inc.
Award(A)Direct893 shares- - Aug 27, 2026FBRX
Forte Biosciences, Inc.
Tender Offer(U)Direct5.9K shares- - Aug 27, 2026FBRX
Forte Biosciences, Inc.
Disposition(D)DirectRestricted Stock Units
18.4K shares- - Aug 27, 2026FBRX
Forte Biosciences, Inc.
Disposition(D)DirectStock Option (right to buy)
2K shares- - Aug 27, 2026FBRX
Forte Biosciences, Inc.
Disposition(D)DirectStock Option (right to buy)
1K shares- - Aug 27, 2026FBRX
Forte Biosciences, Inc.
Disposition(D)DirectStock Option (right to buy)]
2K shares- - Aug 27, 2026FBRX
Forte Biosciences, Inc.
Disposition(D)DirectStock Option (right to buy)
31K shares- - Jun 11, 2026DFTX
Definium Therapeutics, Inc.
Award(A)Direct4.7K shares- - May 29, 2026FBRX
Forte Biosciences, Inc.
Award(A)DirectRestricted Stock Units
18.4K shares- - Jun 12, 2025MNMD
Mind Medicine (MindMed) Inc.
Award(A)DirectStock Option (Right to Buy)
75.2K shares- - Mar 20, 2025FBRX
Forte Biosciences, Inc.
Award(A)DirectStock Option (right to buy)
31K shares- - Dec 5, 2024MNMD
Mind Medicine (MindMed) Inc.
Purchase(P)Direct2.5K shares at avg. $7.17$18K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 |  CELC Celcuity Inc. | Award(A) | 893 | - | $0 | Direct |
| Aug 27, 2026 |  FBRX Forte Biosciences, Inc. | Tender Offer(U) | 5,940 | - | $0 | Direct |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Disposition(D) Restricted Stock Units | 18,353 | - | - | Direct |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Disposition(D) Stock Option (right to buy) | 2,000 | - | - | Direct |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Disposition(D) Stock Option (right to buy) | 1,000 | - | - | Direct |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Disposition(D) Stock Option (right to buy)] | 2,000 | - | - | Direct |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Disposition(D) Stock Option (right to buy) | 31,000 | - | - | Direct |
| Jun 11, 2026 |  DFTX Definium Therapeutics, Inc. | Award(A) | 4,666 | - | $0 | Direct |
| May 29, 2026 | FBRX Forte Biosciences, Inc. | Award(A) Restricted Stock Units | 18,353 | - | - | Direct |
| Jun 12, 2025 |  MNMD Mind Medicine (MindMed) Inc. | Award(A) Stock Option (Right to Buy) | 75,187 | - | - | Direct |
| Mar 20, 2025 | FBRX Forte Biosciences, Inc. | Award(A) Stock Option (right to buy) | 31,000 | - | - | Direct |
| Dec 5, 2024 | MNMD Mind Medicine (MindMed) Inc. | Purchase(P) | 2,500 | $7.17 | $17,925 | Direct |
1-12 of 12 transactions
About GRYSKA DAVID W
GRYSKA DAVID W (SEC CIK 0001202335) files insider reports with the SEC as Director of Celcuity Inc. (CELC), Director of Forte Biosciences, Inc. (FBRX) and Director of Definium Therapeutics, Inc. (DFTX).
Signal8 holds 8 ownership filings by GRYSKA DAVID W (1 Form 3, 7 Form 4), filed between Dec 5, 2024 and Oct 5, 2026. Those filings report 12 transactions, from Dec 5, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on GRYSKA DAVID W's filings is in MINNEAPOLIS, MN.
Recent filings by GRYSKA DAVID W
- Oct 1, 2026: Grant or award of CELC shares (Form 4, code A).
- Aug 27, 2026: Tender of shares transaction of FBRX shares (Form 4, code U).
- Aug 27, 2026: Disposition to issuer transactions of FBRX derivative securities (5 lines, Form 4, code D).
- Jun 11, 2026: Grant or award of DFTX shares (Form 4, code A).
- May 29, 2026: Grant or award of FBRX derivative securities (Form 4, code A).
Other insiders filing for Celcuity Inc. (CELC)
- Furcht Leo, Director
- Laing Lance G., Chief Science Officer
- Sullivan Brian F., Chief Executive Officer
- Hahne Vicky, Chief Financial Officer
- BAKER BROS. ADVISORS LP, Officer
- Murphy Polly A., Director